Pharm

Short-Acting Anticholinergic Bronchodilator

search

Short-Acting Anticholinergic Bronchodilator, Short-Acting Muscarinic Antagonist, Ipratropium, Ipratropium Bromide, Atrovent, Combivent, Combivent Respimat

  • See Also
  1. COPD Management
  2. Asthma Exacerbation
  3. Long-acting Anticholinergic Bronchodilator
  • Indications
  1. Chronic Obstructive Pulmonary Disease (COPD)
    1. Longer acting Anticholinergic Agents are preferred in COPD
    2. See Long-acting Anticholinergic Bronchodilator
  2. Acute Asthma Exacerbation
    1. Used in combination with Albuterol (duoneb)
  • Mechanism
  1. Ipratropium (Atrovent) is a Short-Acting Anticholinergic Bronchodilator
  2. Acts as a Muscarinic Antagonist, reducing Acetylcholine induced bronchospasm
  • Preparations
  • Ipratropium Bromide
  1. Atrovent MDI
    1. Inhale 2-3 puffs three to four times daily as needed (maximum 12 puffs/day)
  2. Atrovent Nebulization (0.02%, 500 mcg/ampule)
    1. Nebulize 1 ampule of Ipratropium solution every 6 to 8 hours as needed
  • Preparations
  • Combination Ipratropium with Albuterol (Combivent)
  1. Combivent (older CFC version)
    1. Will be phased out in 2013 due to CFC
    2. Dose: 2 puffs up to every 6 hours
    3. Contraindicated in soybean or peanut allergy
  2. Combivent Respimat
    1. Dose: 1 puff every 6 hours
    2. Does not carry the Food Allergy related contraindications of the older Combivent
  • Adverse Effects
  1. Serious adverse effects
    1. Anaphylaxis, Angioedema or other Hypersensitivity Reaction
    2. Paradoxical bronchospasm or Laryngospasm
    3. Exacerbation of Glaucoma
    4. Increased cardiovascular events
      1. Avoid short acting Anticholinergics (Ipratropium) in comorbid cardiovascular disease
      2. Ogale (2010) Chest 137(1): 13-19 [PubMed]
      3. Singh (2008) JAMA 300(12): 1439-50 [PubMed]
  2. Common adverse effects
    1. Cough
    2. Dry Mouth or oral irritation
    3. Gastrointestinal upset such as Nausea
    4. Urticaria or other rash
    5. Headache
    6. Nervous Sensation
    7. Urinary Retention
  3. Allergy
    1. Original Atrovent MDI (non-HFA) was contraindicated with soy or peanut allergy
  • Safety
  1. Pregnancy Category B
  2. Unknown safety in Lactation
  • Reources
  1. Ipratropium Bromide Nebulizer Solution (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f625d3e3-c175-4d9a-99ea-dab410b262f1
  2. Ipratropium Bromide and Albuterol Nebulizer Solution (Duoneb, DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bcc115b-88da-4ff0-b4e1-ef10d5287e54
  3. Ipratropium HFA MDI (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=170e98ef-5560-4068-be7d-e649068eb884
  • References
  1. (2022) Inhaled Medications for COPD, Presc Lett, #381116
  2. (2020) Drugs for COPD, Med Lett Drug Ther 62: 137-44